Osteonecrosis in protease inhibitor-treated patients

P. Bonfanti, A. Gabbuti, S. Carradori, L. Pusterla, F. Parazzini, S. Landonio, T. Quirino

Research output: Contribution to journalArticlepeer-review


The introduction of protease inhibitors has proven a watershed in human immunodeficiency virus infection therapy and has initiated an era of highly active anti-retroviral therapy. However, the numerous data on the effectiveness of these therapeutic regimens have been cited with an ever-growing number of communications concerning adverse reactions. In particular, the widescale use of protease inhibitors has underlined a series of events not evidenced in the controlled clinical studies that permitted the registration of these drugs. We are conducting a cohort multicenter study to evaluate the incidence of adverse events during treatment with protease inhibitors. To date, 4 cases of bilateral osteonecrosis of the femoral head have been reported out of 1073 person-years. While the pathogenesis of this event is unclear, it may be a long-term complication of protease inhibitor treatment.

Original languageEnglish
Pages (from-to)271-272
Number of pages2
Issue number3
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine


Dive into the research topics of 'Osteonecrosis in protease inhibitor-treated patients'. Together they form a unique fingerprint.

Cite this